Infinity, AbbVie deal

Infinity said AbbVie ended the companies’ 2014 deal to co-develop and co-commercialize duvelisib ( IPI-145) and returned its rights to Infinity. The oral inhibitor of phosphoinositide-3-kinase ( PI3K...